is reportedly near a tentative agreement with the Justice Department to resolve its antitrust case.
According to various reports, the agreement would require the Redmond, Wash., software maker to drop various restrictions it places on personal-computer makers that had virtually forced them to preload the Windows operating system on new PCs.
The agreement would not, however, require Microsoft to stop bundling certain other software with Windows, an issue that could be unacceptable to states that are also negotiating a settlement with the company.
Earnings Reports & Warnings
reduced its fourth-quarter revenue outlook to a range of $380 million to $400 million, down from a previous range of $400 million to $450 million. The company forecast a loss for the quarter of 7 cents to 8 cents a share. Analysts expect a loss of 4 cents. The company expects to be cash flow positive in 2002 and achieve profitability in the latter part of next year.
reported a third-quarter loss of $1.08 a share, topping Wall Street's estimate by a penny. Revenue rose 24.4% to $1.04 billion, but the company lowered its top line guidance for the full year.
posted third-quarter earnings of 41 cents a share, a penny ahead of estimates. Sales rose 17% to $70.25 million. The company also remains comfortable with its fourth-quarter guidance.
, the parent company of United Airlines, posted a third-quarter loss of $10.05 a share, beating the First Call consensus estimate, which called for a loss of $10.27, an accomplishment the company made a point of noting in its press release. Revenue fell 16.3% from a year ago to $4.11 billion. The company expects to record a fourth-quarter loss, excluding charges, that will be substantially wider than the third-quarter loss.
reported a third-quarter loss of $273 million, or 55 cents a share, meeting estimates. Excluding one-time items, the loss would have been 52 cents.
UBS Warburg removed
from its global tech focus list and replaced it with
Automatic Data Processing
. The firm said the change is based on relative near-term fundamentals and not on the long-term outlook for the companies.
reported that a novel small molecule inhibitor of a protein kinase appears to effectively inhibit the growth of breast and prostate tumors in preclinical studies.
After Wednesday's Close
said the Securities and Exchange Commission has launched a formal investigation into the company's relationship with a series of limited partnerships. The company said it will cooperate with the SEC.